Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Vermillion — Investor Presentation (January 2015)

43 slides from Aspira Women's Health's investor presentation, Jan 12, 2015

  1. Slide 1: Improving Quality of Life for Women Through Diagnostic / Informatic Solutions

    (J VERMILLION’ Improving Quality of Life for Women Through Diagnostic / Informatic Solutions ws SO ASPIRA LABS’ JANUARY 2015 ‘YOUR HEALTH OUR PASSION,

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contain forward-looking statements, as definad in the Private Securities Litigation Reform Act of 1995. Worde such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “zeake,” “could,” "should," “continue,” “wil,” “potential,”

  3. Slide 3: Company Overview

    Company Overview ° Ticker Symbol: VRML (NASDAQ CM) ¢ Market Cap (1-7-2015): $87.1M - Shares Outstanding: 43.1M © Cash and Cash Equivalents (12-31-2014): $22.7M e Enterprise Value: $65.5M © Headquarters Location: Austin, TX LQVERMILION ext wntent tng teed a

  4. Slide 4: Vermillion's Focus is Gynecologic Health

    Vermillion’s Focus is Gynecologic Health Our vision is to be the global leader in personalize: medical management of gynecologic health clinical outcomes for patients, physicians and We accomplish this through collaborations wi scientific and clinical institutions such kins, UCI, MD Anderson, Moffit

  5. Slide 5: Vermillion Accomplishments Since $30M Capital Raise

    Vermillion Accomplishments Since $30M Capital Raise * Oracle Investment Management / Jack W. Schuler take position in 2013 * Development of platform migration for OVA1 * Quest (DGX) alliance agreement terminated by Vermillion « ASPiRA Labs founded / OVA1 testing commences June 2014 ° R&D accelerates

  6. Slide 6: About Vermillion

    About Vermillion + aa

  7. Slide 7: US healthcare system annually spends on gynecologic care

    US healthcare system annually Mass Non-Gya spends $22B on endometriosis emus care’, $5.1B on Ov Ca care? and Cyst $1.2B on PCOS care? 500K ~1M5 98% Ovarian i benign Cancer Deaths Masses : to Surgery Pelvic = a a (QVERMILLION

  8. Slide 8: Large Unmet Clinical Need

    arge Unmet Clinical Need Ovarian cancer stage at presentation and survival a Confined to the ovary 20% 85% Extends to true pelvis 5% 60% Extends beyond the true pelvis 58% 26% Distant disease 17% 12% >70% of ovarian cancers are diagnosed at late stages’ QVeRMILLION

  9. Slide 9: Limitations of current diagnostic approaches

    * Physical exam is specialist * Imaging is subjective jependent * CA-125 used off-label * High rate of false negatives (25-50% dependent * Non-specific - other conditions Dx (liver, Gl, breast) tage.

  10. Slide 10: Vermillion's Current Solution and Impact

    Vermillion’s Current Solution and Impact Ova An FDA-cleared blood test, which assesses the risk of malignancy/appropriately triages high risk patients The OvaCalc® algorithm combines five biomarker results into a single numerical “test value” related to the probability of malignancy Interpret OVA1 o

  11. Slide 11: Vermillion's Current Solution: How It is Used in Practice

    Vermillion’s Current Solution: How It is Used in Practice Ovarian Adnexal Mass Clinical Assessment Surgery Planned + Lower Probability of Malignancy Higher Probability of Malignancy Malignancy Risk Stratification QVeRMILLION

  12. Slide 12: QQVERMILLION evirentenie hp tent

    QQVERMILLION evirentenie hp tent 2

  13. Slide 13: 85% Reduction

    85% Reduction = | Lo ie 50% Rate of DETECTED Bh rateo MISSED CA125-II* Clinical Modified + OVA1 Oval + Impression” ACOG* Clinical Impression

  14. Slide 14: Key Publications

    Key Publications amatiatee land etal, 99 ‘Fist Pt of OVAI.n= 590 index asyin. "Univerty “+ OVA detected 76% of malignancies missed by CA-125 Secinmsrar of Kentucky Patients 6 Ts pertormance of OVAI wae consstentin ear and ate-stage cancers Ovarian mmaigrancy re ca “+ Second pivotal tia of OVAI with

  15. Slide 15: Intellectual Property

    Intellectual Pro Strong IP Protection | Granted | Pending _| QVeRMILLION

  16. Slide 16: OVA1 Key Findings to Date

    OVA1 Key Findings to Date ° Early-stage stratification - 92% of early-stage; 89% of stage | cancers © NPV: 95% to 98% in two pivotal studies * OVA! detected 83% of cancers missed by clinical assessment * OVA1 detected 71% of cancers missed by CA125 - 78% of early-stage and 81% of stage | missed by C

  17. Slide 17: OVA1 Milestones

    OVA1 Milestones First FDA-cleared multi-marker/algorithm blood test * Unique category 1 CPT code from AMA * Medicare coverage at $516 ¢ Among the first class of “MAAA" algorithmic tests to be awarded an AMA code * ASPiRA Labs CLIA lab for direct testing and future LDTs * Proof of concept established

  18. Slide 18: Clinical Impact: Case Studies

  19. Slide 19: Case Study

    r My Patient: 34 y/o, pre-menopausal Visit type: Annual Finding: __ * Right sided pelvic mass — U/S showed 11.49cm X 6.47cm mass * “Large complex right adnexal mass likely of ovarian origin. Irregular borders and echogenic wall. There is also questionable mural nodularity.” * Malignancy indeterminat

  20. Slide 20: Case Study

    Case Study 2 I a VERMILLION Patient: 41 y/o, pre-menopausal Visit type: Pelvic pain Finding: Right sided pelvic mass — U/S showed 5.5 X 8.4 X 9.1m mass * “Moderate right ovarian enlargement. Cyst measuring 3.3 x 3.9 cm in size. There is a small amount of tissue along the posteromedial margin of this

  21. Slide 21: Continuing Product Development

    Continuing Product Development Improvement to OVA1's biomarker technology is now at hand... on (va? Increased specificity and positive predictive value (PPV), maintaining the same high sensitivity and NPV as OVA1, more accurately assorting patients for referral Expected to be launched in Q3 2015

  22. Slide 22: OVA2 - Breakthrough in Ovarian Cancer Management

    OVA2 - Brea ugh in Ovarian Cancer Management Sen: PPV NPV Be. Oval 93% 43% 42% 93% rao 6751959) 7610479) (265t046.9) (@80%096.1) 5 3s BS| ovaz equal ae 8° Deas qual qual 92% 52% 32.47% 93.96% ance statistically uit not statically diferent .ccuracy in pre-surgical prediction of o QVeRMiLtiON

  23. Slide 23: An Evolution in Strategy

    An Evolution in Strategy To radically improve patient care, we need to expand our scope to the larger problem of assorting all pelvic mass patients along the best ment care paths for their disea: 500K to 1M nosed Correct referral for ovarian cancer surgery QVeRmuttion P

  24. Slide 24: An Evolution in Strategy

    An Evolution in Strategy To radically improve patient care, we need to expand our scope to the larger problem of assorting all s along the best management care paths for their disease vic mass patien Correct treatment pathway Benign Gynecologic Malignant Gynecologic Disease QVeRMILLION

  25. Slide 25: An Evolution in Strategy

    An Evolution in Strategy To impact this expanded scope, biomarkers alone are limited in terms of needed algorithm development and accuracy Unparalleled Data Registry @ Gl 9 Imaging/ Clinical Data Other Modalities Biomarkers Algorithm Platform QVeRMittiON

  26. Slide 26: Our Expertise

    Our Expertise OVASERIES % IMAGING FDA Proof of concept studies Biomarkers OVAX, Algorithm development => future Multi-center studies jprseltse Cue. (Total patients in development /publications = 2,500+, plus >70,000 patients tested to date) LQVERMILLION csr tng

  27. Slide 27: TAM and SOM by use

    245K TAM Rule out; ul wai surgical choi progression, recurrence monitoring 75K TAM Guided referral $440M (SOM = 7%) $50M (SOM = 22%)!

  28. Slide 28: The Value of Vermillion's Solution

    The Value of Vermillion’s Solution vee i QVERMILLION ct enone An eet * Improve time to Tx * Low risk: peace of mind * High risk: get to the right specialist * Improved differential Dx * Low risk: keep patient * High risk: refer to Gyn Onc * Increased control of quality outcomes in ACA climate * Best

  29. Slide 29: Vermillion: World Class KOLs and Partners

    Vermillion: World Class KOLs and Pa Multi-marker technology expertise and intellectual property * Algorithm expertise * Exceptional access to relevant samples and clinical data Key partners in managed care and clinical impact ©: as See ‘e) oO Siineaieen Gawaece a Sewn dette Defense QQVERMILLION esto

  30. Slide 30: Achieving the Vision

    Aci g the Vi * Added, scaled modalities * Additional biomarkers * Refined data analysis * Algorithm refinement * One of a kind patient registry Additional cca data ‘nd biomarkers Cve® [ Differential Dx of ) gynecologic disease Ove? ma Adsition of alec modality data se Berign/Malignant Now biomarkers

  31. Slide 31: Added, scaled modalities

    * Added, scaled modalities * Additional biomarkers © Refined data analysis * Algorithm refinement * One of a kind patient registry Additional clinical data ‘ond biomarkers [ Endomationit ‘Ackition of scaled modality data . x Plcacherpiehinm —— eae reais intitstions to enhance algorithm 7PYASPIRALABS

  32. Slide 32: Added, scaled modalities

    ¢ Added, scaled modalities Additional biomarkers © Refined data analysis Algorithm refinement © One of a kind patient registry — DxA Additional clinical data ‘end biomarkers [ Addition of scaled modality data New biomarkers, SEE (maging) to ncresce acity end harvest sensed 5ecsRy data from ASPIRA an

  33. Slide 33: Leveraging Partnerships - Develop OVA*

    Leveraging Partnerships - Develop OVA* Strategic Medical Partners = = OVvA* Collaborative Model Data Analysis and Parsing Partners ndocc Cinical utility studies Economic value studies QVERMILLION:

  34. Slide 34: Future development efforts will require sample collection and partners

    18 2019 2020 Future development efforts will require sample collection, key internal resources, and strong strategic partners QQVERMILLION, existent geet

  35. Slide 35: International

    INTERNATIONAL Top down, high-touch approach to IDNs, systems, ACOs Bottom up low-touch approach to patients, providers S——————-_ (VW Sevice Offering —_—_—_—p as

  36. Slide 36: Track Record of Operating Experience

    Track Record of Operating Experience Valerie Palmieri President and CEO DIANON Systems _ AlabCorp ee || ees } é PD. het Scintte fice Zccoun | consinc G9 lnvitrogen- peng || Gerenayres Brame SE VENTANA Laura Miller SVP Suis / Cabtorner Experience @HealthTronics: {labCorp I> Porkin=nor Ly Holly Bauzon

  37. Slide 37: Vermillion: Anticipated 2015 Milestones

    Ver! ion: Anticipated 2015 Milestones * OVA2 FDA submission / clearance / launch - FDA submission planned - Q1 2015 - FDA clearance and launch expected - Q3 2015 Publish OVA1 cost effectiveness study - Q2 2015 Publication of OVA2 data - 04 2015 * NCCN Guideline submission - Solicit new SGO position

  38. Slide 38: 2015 Financial Priorities

    2015 Financial Priorities ° Price (maintain / build value) * Sales ramp / penetration (build on existing market share / call point) ° Margins (>80% over 2015 - 2019) * Reimbursement - revenue cycle management LQVERMILION —ctntnnc sents i

  39. Slide 39: ‘ova

    ‘ova ao pare vA onicpstor sucles— eS. “NCKH EO) wmindex ASCO, ACOS oes ‘guidelines Gainpositve Increase in Medical Policy Medical Policy contracting for for DxA*Aute atmajorhealth —“Ova2 ~3 fusting contracts add to.existing lane ‘coverage ‘contracts

  40. Slide 40: Sustainable Advantages, Tailwinds and Headwinds

    Sustainable Advantages, Tailwinds and Headwinds Sustainable Advantages * Biomarker IP * Trade secret algorithm © ASPiRA Labs data structure and source Tailwinds * OVA2 on schedule * FDA process experience * Robust clinical/ financial publication pipeline © Proven clinical partners Headwinds * Payer

  41. Slide 41: Vermillion's Strategy: Built for the Future

    Ver! ion’s Strategy: Built for the Future FDA-cleared product Unique Category 1 CPT code (AMA) epplied for Medicare Coverage/Gap Fill Pricing IVD kit CLIA lab for LDTs Multi-modal predictive analytics Proprietary disease registry/samples Leading peer-reviewed publications RRA KR KERN KAA KR KK AX KA

  42. Slide 42: Conclusion

    Conclu: ¢ First of its kind, FDA-cleared multi-variate technology platform * OVAT is clinically validated to reduce cancers missed by >80% * Market leader expertise: biomarkers, algorithm development and clinical/data partnering to develop solutions © Risks mitigated - Strong barriers to entry (50 p

  43. Slide 43: Corporate Headquarters and Investor Relations

    QVeRmie Corporate Headquarters 12117 Bee Caves Rd. Building Ill, Suite 100, Austin, TX 78738 Tel: (512) 519.0400 Fax: (512) 439.6980 Investor Relations Michael Wood LifeSci Advisors LLC Tel: (646) 597 6983 mwood@lifesciadvisors.com a

Vermillion — Investor Presentation (January 2015) on 6ix